Peringatan Keamanan

Patients experiencing an overdose may present with unsteady gait, slurred speech, nystagmus, confusion, poor judgement, irritability, and insomnia.L13613 Acute overdoses may present as CNS depression, respiratory depression, oligouria, tachycardia, hypotension, low body temperature, coma, and shock.L13613 An extreme overdose can lead to a flat EEG, resembling death, that is reversible provided there is no hypoxic brain damage.L13613 Overdose can be treated with symptomatic and supportive treatment.L13613

Butabarbital

DB00237

small molecule approved illicit

Deskripsi

Butabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates.A201977,L13613 This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.A201977,L13613 Butabarbital is less commonly used in recent years, as more patients are typically prescribed benzodiazepines.A19735 Its short duration of action gives butabarbital a high abuse potential, comparable to secobarbital.A201977,A201980

Butabarbital was granted FDA approval on 5 June 1939.L13613

Struktur Molekul 2D

Berat 212.2456
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Butabarbital has a half life of 100 hours but its duration of action is only 6-8 hours.[L13613]
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data regarding the metabolism of butabarbital in humans are not readily available. In dogs, butabarbital undergoes metabolism to a final glucuronide metabolite.A202043

Rute Eliminasi

Barbiturates such as butabarbital are predominantly eliminated in the urine.A202031,A202040,L13613 In dogs, 3-5% of the dose is eliminated in the urine as the unchanged parent compound.A202043

Interaksi Makanan

1 Data
  • 1. Avoid alcohol. Concomitant use of alcohol and barbiturates may lead to increased.

Interaksi Obat

1646 Data
Buprenorphine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Hydrocodone Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Magnesium sulfate The therapeutic efficacy of Butabarbital can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Butabarbital may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Mirtazapine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Orphenadrine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Pramipexole Butabarbital may increase the sedative activities of Pramipexole.
Ropinirole Butabarbital may increase the sedative activities of Ropinirole.
Rotigotine Butabarbital may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Butabarbital.
Suvorexant Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Thalidomide Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Butabarbital.
Propacetamol The metabolism of Propacetamol can be increased when combined with Butabarbital.
Acetaminophen The metabolism of Acetaminophen can be increased when combined with Butabarbital.
Chloramphenicol The metabolism of Butabarbital can be decreased when combined with Chloramphenicol.
Doxycycline The serum concentration of Doxycycline can be decreased when it is combined with Butabarbital.
Felbamate The serum concentration of Butabarbital can be increased when it is combined with Felbamate.
Griseofulvin The serum concentration of Griseofulvin can be decreased when it is combined with Butabarbital.
Lamotrigine The serum concentration of Lamotrigine can be decreased when it is combined with Butabarbital.
Mianserin Mianserin may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Pyridoxine The metabolism of Butabarbital can be increased when combined with Pyridoxine.
Teniposide The serum concentration of Teniposide can be decreased when it is combined with Butabarbital.
Ulipristal The serum concentration of Ulipristal can be decreased when it is combined with Butabarbital.
Voriconazole The serum concentration of Voriconazole can be decreased when it is combined with Butabarbital.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Butabarbital.
Sodium oxybate Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Aminophylline The therapeutic efficacy of Butabarbital can be decreased when used in combination with Aminophylline.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum toxin type A.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Butabarbital is combined with Botulinum toxin type B.
Meperidine Butabarbital may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Meperidine.
Somatostatin The risk or severity of adverse effects can be increased when Somatostatin is combined with Butabarbital.
Ethanol Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.
Fluvoxamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Butabarbital is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Butabarbital is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Butabarbital is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Butabarbital is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Seproxetine.
Levomilnacipran Butabarbital may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.
Indalpine The risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Butabarbital is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Butabarbital is combined with Alaproclate.
Naltrexone The risk or severity of adverse effects can be increased when Butabarbital is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Butabarbital is combined with Bezitramide.
Morphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine.
Hydromorphone The risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone.
Oxycodone The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Butabarbital is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Butabarbital is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Alfentanil.
Nalbuphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Butabarbital is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil.
Diphenoxylate The risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Butabarbital is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Butabarbital is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Butabarbital is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Butabarbital is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine.
Ketobemidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Butabarbital is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Butabarbital is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Butabarbital is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Butabarbital is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Butabarbital is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Nicomorphine.

Target Protein

GABA(A) Receptor GABRA1
Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1
Neuronal Acetylcholine (nACh) Receptor Subunits CHRNA10
Glutamate receptor 1 GRIA1
Glutamate receptor 2 GRIA2
Glutamate receptor 3 GRIA3
Glutamate receptor 4 GRIA4
Glutamate receptor ionotropic, kainate 1 GRIK1
Glutamate receptor ionotropic, kainate 2 GRIK2
Glutamate receptor ionotropic, kainate 3 GRIK3
Glutamate receptor ionotropic, kainate 4 GRIK4
Glutamate receptor ionotropic, kainate 5 GRIK5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 18103391
    DRIPPS RD: Selective utilization of barbiturates as illustrated by a study of butabarbital sodium. J Am Med Assoc. 1948 Jan 15;139(3):148-50.
  • PMID: 12826989
    Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM: Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. J Clin Psychopharmacol. 2003 Jun;23(3):269-80. doi: 10.1097/01.jcp.0000084031.22282.24.
  • PMID: 18568113
    Lopez-Munoz F, Ucha-Udabe R, Alamo C: The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005 Dec;1(4):329-43.
  • PMID: 13175102
    GOLDBAUM LR, SMITH PK: The interaction of barbiturates with serum albumin and its possible relation to their disposition and pharmacological actions. J Pharmacol Exp Ther. 1954 Jun;111(2):197-209.
  • PMID: 10703988
    Martin-Biosca Y, Sagrado S, Villaneuva-Camanas RM, Medina-Hernandez MJ: Determination of barbiturates in urine by micellar liquid chromatography and direct injection of sample. J Pharm Biomed Anal. 1999 Nov;21(2):331-8. doi: 10.1016/s0731-7085(99)00147-8.
  • PMID: 6834253
    Tang-Liu DD, Tozer TN, Riegelman S: Dependence of renal clearance on urine flow: a mathematical model and its application. J Pharm Sci. 1983 Feb;72(2):154-8. doi: 10.1002/jps.2600720215.
  • PMID: 13272177
    MAYNERT EW, LOSIN L: The metabolism of butabarbital (butisol) in the dog. J Pharmacol Exp Ther. 1955 Nov;115(3):275-82.
  • PMID: 11264449
    Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51.
Menampilkan 8 dari 11 artikel.

Contoh Produk & Brand

Produk: 9 • International brands: 3
Produk
  • Butisol Sodium
    Tablet • 50 mg/1 • Oral • US • Approved
  • Butisol Sodium
    Solution • 30 mg/5mL • Oral • US • Approved
  • Butisol Sodium
    Tablet • 30 mg/1 • Oral • US • Approved
  • Butisol Sodium Tab 100mg
    Tablet • 100 mg / tab • Oral • Canada • Approved
  • Butisol Sodium Tab 15mg
    Tablet • 15 mg / tab • Oral • Canada • Approved
  • Butisol Sodium Tab 30mg
    Tablet • 30 mg / tab • Oral • Canada • Approved
  • Phenazopyridine Hydrochloride, Hyoscyamine Hydrobromide, and Butabarbital
    Tablet, coated • - • Oral • US
  • Phenazopyridine Plus
    Tablet, coated • - • Oral • US
Menampilkan 8 dari 9 produk.
International Brands
  • Butalan
  • Butisol
  • Sarisol No. 2

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul